Abstract
Antigen-presenting cells (APCs) play a pivotal role in cancer immunotherapy. APCs in conventionally used flasks are harvested by enzymatic digestion or cell scraping for application to cancer immunotherapy. However, these methods may impair functional molecules expressed on the APC surface and reduce their effects in cancer immunotherapy. Recently, we found that APCs could be harvested by shaking at 4°C in flasks coated with poly[N-p-vinylbenzyl-O-2-acetoamide-2-deoxy-β-D-glucopyranosyl-(1→4)-2-acetoamide-2-deoxy-β-D-gluconamide] (PVGlcNAc) or a copolymer consisting of sulfonylurea (SU) linked to poly[N-p-vinyl-benzyl-4-O-β-D-galactopyranosyl-D-gluconamide] [P(VLA-co-SU)]. In the present study, we compared the functions of cytotoxic T-lymphocytes (CTLs) induced by APCs generated in PVGlcNAc- or P(VLA-co-SU)-coated flasks and conventional flasks. APCs from PVGlcNAc- or P(VLA-co-SU)-coated flasks showed higher expression of cluster of differentiation (CD)80/86, CD11c, and major histocompatibility complex class II alloantigen I-Ad, and higher cytotoxicity than APCs from conventional flasks. These results suggest that the use of PVGlcNAc- or P(VLA-co-SU)-coated flasks is optimal for harvesting APCs. The generated APCs also have a higher antigen-presenting ability compared to those generated in conventional flasks. Our results may contribute to the development of effective cancer immunotherapies.
Antigen-presenting cells (APCs), such as monocytes, macrophages, and dendritic cells (DCs), play pivotal roles in cancer immunotherapy. For use in cancer immunotherapy, these cells are often harvested by enzymatic digestion using trypsin/EDTA or cell scraping. The current methods may impair functional molecules expressed on the cell surface because of their digestion and reduce their effects in cancer immunotherapy. Moreover, these procedures also require a skilled technician and are not standardized. Thus, there should be reconsideration regarding the procedure for harvesting APCs.
Previous studies show that poly[N-p-vinyl-benzyl-4-O-β-D-galactopyranosyl-D-gluconamide] (PVLA)-coated dishes are useful for hepatocyte-specific culture systems (1-4). It has also been revealed that poly[N-p-vinylbenzyl-O-2-acetoamide-2-deoxy-β-D-glucopyranosyl-(1→4)-2-acetoamide-2-deoxy-β-D-gluconamide] (PVGlcNAc)-coated dishes serve as an artificial extracellular matrix for non-parenchymal cells (5). Recently, we found that APCs could be generated and harvested easily with the use of these coated flasks by reducing the culture temperature to 4°C and shaking.
In the present study, we investigated the functions of APCs obtained using PVGlcNA-c and PVLA-coated flasks.
Materials and Methods
Mice. Male C57BL/6 (H-2b) and BALB/c (H-2d) mice between 6 and 7 weeks of age were obtained from Oriental Yeast Co., ltd. (Tokyo, Japan). Animals were specific pathogen-free and had free access to food and water in the animal care facility under the Institutional guidelines for the usage of experimental animals.
Mononuclear leukocytes (MNLs). C57BL/6 (H-2b) and BALB/c (H-2d) mice were sacrificed and their spleens and lymph nodes were removed aseptically. MNLs were obtained by mincing lymphoid organs, followed by passing through a cotton wool column and washing with RPMI-1640 (Gibco, Grand Island, NY, USA) supplemented with 10% fetal bovine serum (JRH BioSciences, Tokyo, Japan), 5×10−5 M 2-mercaptoethanol (Sigma–Aldrich, St. Louis, MO, USA,), 10 mM HEPES (Sigma Chemical Co. St. Louis, MO, USA), 100 μg/ml penicillin (Meijiseika, Tokyo, Japan), and 100 μg/ml streptomycin (Meijiseika) (referred to as MLR medium).
Target MNLs as antigens. MNLs from C57BL/6 (H-2b) or BALB/c (H-2d) mice were treated with concanavalin A (20 μg/ml; Sigma Chemical Co.) for 48 h at 37°C and then mitomycin C (MMC, 50 μg/ml; Sigma Chemical Co.) for 1 h at 37°C to stop proliferation. The cells were then used as target cells. Target MNLs from C57BL/6 (H-2b) mice were used as allogeneic antigens and those from BALB/c (H-2d) mice were used as syngeneic antigens.
Induction of APCs. Naive MNLs from BALB/c (H-2d) mice (6×107 cells/ml) and C57BL/6 (H-2b) mice (6×107 cells) were co-cultured in T-75 flasks (Becton Dickinson, Franklin Lakes, NJ, USA) containing 24 ml MLR medium at 37°C for 12 days. Other flasks (Becton Dickinson) were coated with PVGlcNAc or a PVLA derivative co-polymer consisting of sulfonylurea linked to PVLA [P(VLA-co-SU)]. APCs attached to conventional flasks were harvested by three methods: i) mechanical shaking on ice (4°C), ii) enzymatic digestion, and iii) pipetting. Cells attached to PVGlcNAc- and P(VLA-co-SU)-coated flasks were harvested by mechanical shaking at 4°C.
Mixed leukocyte reaction (MLR). To obtain T-helper (Th) cells, we performed a primary MLR. The techniques of primary and secondary MLRs have been described previously (6). Briefly, the MLR was performed for 10-14 days using naive MNLs from BALB/c mice (6×107 cells/ml) and target MNLs (6×107 cells/ml) with APCs in T-75 flasks containing MLR medium supplemented with interleukin-2 (20 ng/ml; Sigma Chemical Co.). Then non-adherent primed cells were harvested. These primed cells were re-stimulated at approximately 5×104/ml in the presence of irradiated stimulator spleen cells of the appropriate haplotype at 4×106/ml in 15 ml MLR medium supplemented with 20 ng/ml interleukin-2 and used as primed Th cells.
Secondary MLR was performed to obtain cytotoxic T-lymphocytes (CTLs). Primed Th1 cells obtained by primary MLR and naive MNLs from BALB/c mice were co-cultured for 10-14 days in T-75 flasks containing MLR medium supplemented with 20 ng/ml interleukin-2. Then non-adherent cells were harvested as CTLs.
7-Aminoactinomycin D (7-AAD) assay. CTLs from BALB/c (H-2d) mice and target MNL from C57BL/6 (H-2b) mice were co-cultured in MLR medium for 2 days. Then, samples (1×106 cells) were stained with fluorescein isothiocyanate (FITC)-anti mouse H-2Db antibody that specifically bound with target MNL from C57BL/6 mice for 30 min at 4°C. After washing once, 5 μg/ml of 7-AAD (Sigma Chemical Co.) were added. The percentage specific cytotoxicity was calculated as following; % specific cytotoxicity =100 × [(H-2b/7-AAD double positive cell number)test cell − (H-2b/7-AAD double positive cell number)negative control]/total cell number.
Fluorescence-activated cell sorting (FACS). To analyze the expression of CD80, CD86, CD11c and I-Ad on APCs, the cells were incubated for 1 h with FITC-conjugated antibody to CD11c, biotin-conjugated antibody against CD80, biotin-conjugated antibody against CD86 and phycoerythrin-conjugated-I-Ad antibody (BD Pharmingen, San Diego, CA, USA). Mouse IgG was used as an isotype control (BD Pharmingen). For staining, cells were washed twice with phosphate-buffered saline (PBS) and were incubated in PBS containing 3% bovine serum albumin (Sigma, St. Louis, MO, USA) and 0.1% NaN3 (FACS buffer; Sigma) and the appropriate concentration of labeled for 1 h at 4°C. After washing with FACS buffer, the expression-positive cells were measured using a FACSCalibur flow cytometer (BD Bioscience, Franklin Lakes, NJ, USA) by 3-color analysis and analyzed with CELLQuest software (BD Bioscience).
Results
Numbers of harvested APCs generated in each flask. Firstly, the number of collected APCs cultured in PVGlcNAc- and P(VLA-co-SU)-coated flasks was compared with that in conventional flasks. The number of APCs harvested from PVGlcNAc- and P(VLA-co-SU)-coated flasks by shaking at 4°C was higher than that of APCs harvested from conventional flask by shaking at 4°C or pipetting (Figure 1). On the other hand, the number of APCs harvested from PVGlcNAc- and P(VLA-co-SU)-coated flasks by shaking at 4°C was almost the same as that of APCs harvested with trypsin/EDTA (Figure 1).
CD80, CD86, CD11c and I-Ad expression in APCs after primary MLR. CD80/86/CD11c/I-Ad expression in APCs cultured in PVGlcNAc- or P(VLA-co-SU)-coated flasks was higher than that in APCs harvested from conventional flask by all three methods (Figure 2). These results suggest that APCs from PVGlcNAc- and P(VLA-co-SU)-coated flasks may have a high antigen-presenting ability.
Alloantigen-specific CTL induction with MNLs from MLR culture. When allogeneic antigens were used in all MLR steps, the cytotoxicity of CTLs primed by APCs harvested from PVGlcNAc- or P(VLA-co-SU)-coated flasks was higher than that of CTLs primed by APCs harvested from conventional flask (A-A-A in Figure 3). When syngeneic antigens or no antigens were used in primary MLR (non-specific reactions), the cytotoxicity of CTLs primed by APCs harvested from PVGlcNAc- or P(VLA-co-SU)-coated flasks was reduced to the same level as that of CTLs primed by APCs harvested from conventional flasks (S-A-A, S-S-A, and N-S-A in Figure 3). These results suggest that APCs from PVGlcNAc- or P(VLA-co-SU)-coated flasks may have a high ability for antigen presentation compared to those from conventional flasks.
Discussion
We previously demonstrated a new method for rapid CTL induction for cancer immunotherapy using a multiple cytokine cocktail to avoid prolonged culture and unexpected contamination (7). In addition to rapidity in the induction of CTLs, acquisition of many well-functioning APCs is important in order to generate CTLs for effective treatment.
Antigen-presenting cells (APCs) attached to conventionally used flask were harvested by three methods: i) mechanical shaking on ice (4°C); ii) enzyme digestion using trypsin/EDTA; iii) pipetting. APCs cultured in poly[N-p-vinylbenzyl-O-2-acetoamide-2-deoxy-β-D-glucopyranosyl- (1→4)-2-acetoamide-2-deoxy-β-D-gluconamide] (PVGlcNAc)-coated flask and a copolymer consisting of sulfonylurea (SU) linked to poly[N-p-vinyl-benzyl-4-O-β-D-galactopyranosyl-D-gluconamide] [P(VLA-co-SU)] coated flask were harvested by shaking at 4°C then the number of harvested APCs was counted under light microscopy. Data shown are representative results of three independent experiments.
Antigen-presenting cells (APCs) attached in conventionally used flasks were harvested by three methods, as follows: i) mechanical shaking on ice (4°C); ii) enzyme digestion using trypsin/EDTA; iii) pipetting. APCs attached in poly[N-p-vinylbenzyl-O-2-acetoamide-2-deoxy-β-D-glucopyranosyl-(1→4)-2-acetoamide-2-deoxy-β-D-gluconamide] (PVGlcNAc)-coated flasks and a copolymer consisting of sulfonylurea (SU) linked to poly[N-p-vinyl-benzyl-4-O-β-D-galactopyranosyl-D-gluconamide] [P(VLA-co-SU)]-coated flasks were harvested by shaking at 4°C. After harvesting APCs, the expressions of cluster of differentiation (CD)80/86, CD11c and major histocompatibility complex class II alloantigen I-Ad were analyzed by fluorescence-activated cell sorting. Data shown are representative results in three independent experiments.
In cancer immunotherapy, DCs from patients with cancer play pivotal roles as APCs. At the immature stage, DCs are easy to harvest because they do not tightly attach to the flask. However, at the mature stage, DCs attach to the flask tightly and are difficult to collect (8). In addition, DCs derived from patients with advanced cancer are difficult to expand and their abilities show impairment compared to those derived from healthy volunteers (8, 9). On the other hand, sufficient numbers of cells may not be harvested from conventional flasks by just shaking or pipetting (Figure 1). Using trypsin/EDTA or a cell scraper, functional molecules of APCs were impaired, as shown in Figure 2. Therefore, an effective methodology is desired to generate and harvest DCs and monocytes. For these purposes, we strongly recommend PVGlcNAc- or P(VLA-co-SU)-coated flasks.
Cytotoxic T-lymphocytes (CTLs) were induced by primary mixed leukocyte reaction (MLR) and secondary MLR. The cytotoxicity of the obtained CTLs was estimated by 7-aminoactinomycin D (7-ADD) dead-cell exclusion test. Dead target cells [C57BL/6 (H-2b) mice] were identified by double staining with antibody to mouse major histocompatibility complex class I alloantigen H-2Db and 7-ADD by fluorescence-activated cell sorting. ‘A’ in the legend indicates that alloantigens, namely mononuclear leukocytes (MNL) from C57BL/6 (H-2b) mice, were used as target cells. ‘S’ in the legend indicates that syngeneic antigen, namely MNL from BALB/c (H-2d) mice were used as target cells. ‘N’ in the legend means no antigens were used. First letter (e.g. S from S-A-A) shows primary MLR, second letter shows secondary MLR and third letter reveals cytotoxic assay. PVGlcNAc: poly[N-p-vinylbenzyl-O-2-acetoamide-2-deoxy-β-D-glucopyranosyl-(1→4)-2-acetoamide-2-deoxy-β-D-gluconamide]; P(VLA-co-SU): a co-polymer consisting of sulfonylurea (SU) linked to poly[N-p-vinyl-benzyl-4-O-β-D-galactopyranosyl-D-gluconamide]; Con A: concanavalin A. Data shown are representative results of three independent experiments.
PVLA was developed as a synthetic glycoconjugate that adsorbs to plastic plates, which possesses unique properties as a substratum, thereby mediating interaction with carbohydrate receptors (10). Similarly to PVLA, PVGlcNAc has been shown to be a multivalent glycoside polymer (11). We believe that the mechanism of easy harvesting from PVGlcNAc- and P(VLA-co-SU)-coated flasks at 4°C is a due to change in the end polymer from hydrophobic to hydrophilic by reducing the temperature. Experiments to confirm this hypothesis are in progress.
In conclusion, we showed that APCs cultured in PVGlcNAc- or P(VLA-co-SU)-coated flasks attach and generate well at 37°C, perform sufficient antigen-presenting functions, and detach well at 4°C. Because no particular technical skill is necessary for APC induction via this method using PVGlcNAc- or P(VLA-co-SU)-coated flasks, standardizing of the culture system is possible. Our results may facilitate establishment of new in vitro investigation methods and contribute to the development of effective cancer immunotherapies.
Acknowledgements
This study was supported by a Kakenhi Grant (15K10055) from the Japan Society for the Promotion of Science. The Authors thank Ms Kaori Nomiyama for skillful technical assistance.
Footnotes
↵* These Authors contributed equally to this study.
Conflicts of interest
The Authors declare no conflicts of interest in regard to this work.
- Received December 15, 2015.
- Revision received January 19, 2016.
- Accepted January 20, 2016.
- Copyright© 2016 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved








